WithdrawnPhase 3NCT02576275
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
Studying Indolent B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SecuraBio
- Principal Investigator
- Hagop Youssoufian, MD, M.DVerastem, Inc.
- Intervention
- Duvelisib(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2016
Study locations (7)
- Plainville, Connecticut, United States
- Plantation, Florida, United States
- Thomasville, Georgia, United States
- East Setauket, New York, United States
- Cookeville, Tennessee, United States
- Knoxville, Tennessee, United States
- Spokane, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02576275 on ClinicalTrials.govOther trials for Indolent B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07166419Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic LeukemiaOhio State University Comprehensive Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07098364ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell LymphomaFred Hutchinson Cancer Center
- RECRUITINGPHASE3NCT07029217A Study of Reduced Dose Radiation Therapy for People With B-Cell LymphomasMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE2NCT06458439Epcoritamab-CAR T Cells for Large B-cell LymphomasAbramson Cancer Center at Penn Medicine
- RECRUITINGPHASE2NCT06442475Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06386315Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin LymphomaMayo Clinic
- RECRUITINGPHASE2NCT06350318Rituximab and Zanubrutinib in Patients With Indolent B-cell LymphomasH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGPHASE1NCT06209619CC-99282 + Rituximab Early Post CART for Non-Hodgkin's LymphomaNathan Denlinger